-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CompilationFan Dongdong
A few days ago, Vertex Pharmaceuticals said that it has begun early clinical trials for the experimental treatment of diabetes stem cell therapy VX-880 for patients with type 1 diabetes.
VX-880 is the first research stem cell-derived therapy that can use fully differentiated insulin-producing pancreatic islet cells to treat type 1 diabetes.
Type 1 diabetes is a disease that plagues millions of people around the world.
The Phase 1/2 single-arm, open-label clinical study will be conducted in multiple locations in the United States, and 17 subjects are expected to be recruited.
Reference source:
1.
2.